APOC3 ASO olezarsen lowers triglycerides; Balance trial

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
ACC.24 - Results of the Balance trial showed that the APOC3 ASO olezarsen reduces triglycerides in patients with familial chylomicronemia syndrome (FCS). The data of the secondary outcome of new-onset pancreatitis were quite astonishing, according to Erik Stroes.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Center in Amsterdam, The Netherlands.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of Balance were simultaneously published in N Engl J Med.
Release date: 10 april 2024

Recommended

Details

Presenters

Overview
ACC.24 - Results of the Balance trial showed that the APOC3 ASO olezarsen reduces triglycerides in patients with familial chylomicronemia syndrome (FCS). The data of the secondary outcome of new-onset pancreatitis were quite astonishing, according to Erik Stroes.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Center in Amsterdam, The Netherlands.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of Balance were simultaneously published in N Engl J Med.
Release date: 10 april 2024

Promising results for APOC3 ASO in familial chylomicronemia syndrome